Author:
Fraser M. D.,Vallin H. E.,Davies J. R. T.,Rowlands G. E.,Chang X.
Abstract
AbstractAlzheimer’s disease (AD) is a disorder associated with progressive degeneration of memory and cognitive function. Galantamine is a licenced treatment for AD but supplies of the plant alkaloid that it is produced from, galanthamine, are limited. This three-year system study tested the potential to combine Narcissus-derived galanthamine production with grassland-based ruminant production. Replicate plots of permanent pasture were prepared with and without bulbs of Narcissus pseudonarcissus sown as lines into the sward. Two different fertiliser regimes were imposed. The above-ground green biomass of N. pseudonarcissus was harvested in early spring and the galanthamine yield determined. In the second harvest year a split-plot design was implemented with lines of N. pseudonarcissus cut annually and biennially. All plots were subsequently grazed by ewes and lambs and animal performance recorded. Incorporation of N. pseudonarcissus into grazed permanent pasture had no detrimental effects on the health or performance of the sheep which subsequently grazed the pasture. There was no consistency to the effects of fertiliser rates on galanthamine yields. There was no difference in overall galanthamine yield if N. pseudonarcissus was cut biennially (1.64 vs. 1.75 kg galanthamine/ha for annual combined vs biennial cuts respectively; s.e.d = 0.117 kg galanthamine/ha; ns). This study verified the feasibility of a dual cropping approach to producing plant-derived galanthamine.
Funder
Biotechnology and Biological Sciences Research Council
Innovate UK
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Prince, M. et al. World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends (Alzheimer’s Disease International, London, 2015).
2. Alzheimer’s Association. Alzheimer’s Disease Facts and Figures. Alzheimer’s Dementia 11, 332–384 (2015).
3. Heinrich, M. & Teoh, H. L. Galanthamine from snowdrop - the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J. Ethnopharmacol. 92, 147–162. https://doi.org/10.1016/s0378-8741(04)00073-x (2004).
4. Wilcock, G. K., Lilienfeld, S., Gaens, E. & Galantamine International S. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Br. Med. J. 321, 1445–1449. https://doi.org/10.1136/bmj.321.7274.1445 (2000).
5. Haake, A., Nguyen, K., Friedman, L., Chakkamparambil, B. & Grossberg, G. T. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Exp. Opin. Drug Saf. 19, 147–157. https://doi.org/10.1080/14740338.2020.1721456 (2020).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献